M
Michael Huber
Researcher at University of Zurich
Publications - 221
Citations - 10749
Michael Huber is an academic researcher from University of Zurich. The author has contributed to research in topics: Mast cell & Signal transduction. The author has an hindex of 44, co-authored 196 publications receiving 9546 citations. Previous affiliations of Michael Huber include Ragon Institute of MGH, MIT and Harvard & Max Planck Society.
Papers
More filters
Journal ArticleDOI
Broad neutralization coverage of HIV by multiple highly potent antibodies
Laura M. Walker,Michael Huber,Michael Huber,Katie J. Doores,Katie J. Doores,Emilia Falkowska,Emilia Falkowska,Robert Pejchal,Jean-Philippe Julien,Sheng-Kai Wang,Alejandra Ramos,Po-Ying Chan-Hui,Matthew Moyle,Jennifer L. Mitcham,Phillip W. Hammond,Ole A. Olsen,Pham Phung,Steven P. Fling,Chi-Huey Wong,Sanjay Phogat,Terri Wrin,Melissa Simek,Protocol G. Principal Investigators,Wayne C. Koff,Ian A. Wilson,Dennis R. Burton,Dennis R. Burton,Pascal Poignard,Pascal Poignard +28 more
TL;DR: Analysis of neutralization by the full complement of anti-HIV broadly neutralizing monoclonal antibodies now available reveals that certain combinations of antibodies should offer markedly more favourable coverage of the enormous diversity of global circulating viruses than others and these combinations might be sought in active or passive immunization regimes.
Journal ArticleDOI
CD14 is required for MyD88-independent LPS signaling
Zhengfan Jiang,Philippe Georgel,Xin Du,Louis Shamel,Sosathya Sovath,Suzanne Mudd,Michael Huber,Christoph Kalis,Simone Keck,Chris Galanos,Marina A. Freudenberg,Bruce Beutler +11 more
TL;DR: The recessive mutation 'Heedless' (hdl) was detected in third-generation N-ethyl-N-nitrosourea–mutated mice that showed defective responses to microbial inducers, and the data suggest that the TLR4–MD-2 complex distinguishes LPS chemotypes, but CD14 nullifies this distinction.
Journal ArticleDOI
Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies
Alexandra Trkola,Herbert Kuster,Peter Rusert,Beda Joos,Marek Fischer,Christine Leemann,Amapola Manrique,Michael Huber,Manuela Rehr,Annette Oxenius,Rainer Weber,Gabriela Stiegler,Brigitta Vcelar,Hermann Katinger,Leonardo Aceto,Huldrych F. Günthard +15 more
TL;DR: Escape mutant analysis showed that the activity of 2G12 was crucial for the in vivo effect of the neutralizing antibody cocktail, and underline both the potential and the limits of humoral immunity in controlling HIV-1 infection.
Journal ArticleDOI
Progressive derangement of periinfarct viable tissue in ischemic stroke.
Wolf-Dieter Heiss,Michael Huber,Gereon R. Fink,Karl Herholz,Uwe Pietrzyk,Rainer Wagner,Klaus Wienhard +6 more
TL;DR: Evidence of viable tissue in the border zone of ischemia up to 48 h after stroke is furnished, while this viable peri-infarct tissue exhibits some potential for effective treatment of ischemic stroke.
Journal ArticleDOI
Monomeric IgE stimulates signaling pathways in mast cells that lead to cytokine production and cell survival.
Janet Kalesnikoff,Michael Huber,Vivian Lam,Jacqueline E. Damen,Juan Zhang,Reuben P. Siraganian,Gerald Krystal +6 more
TL;DR: It is demonstrated that monomeric IgE (mIgE) in the absence of antigen (Ag) stimulates multiple phosphorylation events in normal murine bone marrow-derived mast cells (BMMCs) and leads to a more potent production of cytokines than IgE + Ag.